How well does MEXTOVI(Binimetinib) work?

Clinical trials demonstrated significant improvement in progression-free survival compared to vemurafenib.

Clinical Outcomes

In the COLUMBUS trial for melanoma, the combination of MEXTOVI and encorafenib demonstrated a statistically significant improvement in median progression-free survival (14.9 months) compared to vemurafenib (7.3 months), with a hazard ratio of 0.54. The objective response rate was 63%. In the PHAROS trial for NSCLC, treatment-naïve patients showed an ORR of 75%, while previously-treated patients had an ORR of 46%, confirming the regimen's efficacy in these specific BRAF-mutant populations.